Pharmacy Market

The Globalization Of The Pharmaceutical Industry

July 7, 2023

The Globalization Of The Pharmaceutical
Rapid globalization has brought both opportunity and challenges for the pharmaceutical industry. Established healthcare markets are placing increased demands on industry to ensure products are beneficial, safe and available for patients and to improve how information is shared.

Spotlight

Pharmaceutical Compliance Monitor

Pharma Compliance Monitor (PCM) is only publication that spotlights regulatory and compliance news and developments for the pharmaceutical and biotechnology communities. PCM’s ongoing goal is to create a place where pharmaceutical and biotechnology professionals and executives can go to stay informed, interact and learn. Read by senior compliance professionals and executives at many of the largest research-based pharmaceutical and biotechonology manufacturers, PCM speaks to the decision maker faced with making mission critical choices that anchor best-in-class corporate compliance and ethics programs.

OTHER WHITEPAPERS
news image

Non-Clinical Testing Considerations: Drugs vs Devices

whitePaper | November 8, 2022

While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most important difference is that medical devices do not achieve their principal action by pharmacological means.

Read More
news image

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

Read More
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

Read More
news image

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

whitePaper | November 18, 2022

To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.

Read More
news image

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More

Spotlight

Pharmaceutical Compliance Monitor

Pharma Compliance Monitor (PCM) is only publication that spotlights regulatory and compliance news and developments for the pharmaceutical and biotechnology communities. PCM’s ongoing goal is to create a place where pharmaceutical and biotechnology professionals and executives can go to stay informed, interact and learn. Read by senior compliance professionals and executives at many of the largest research-based pharmaceutical and biotechonology manufacturers, PCM speaks to the decision maker faced with making mission critical choices that anchor best-in-class corporate compliance and ethics programs.

Events